Table 1.
Correlation of CD123 expression with clinicopathological features of pediatric B-ALL patients treated with CCLG-ALL-2008 protocol.
| Feature | Category | Total | CD123 | p value | |||||
|---|---|---|---|---|---|---|---|---|---|
| Negative | Low percentage | High percentage | |||||||
| All | 328 | 82 | 25.0% | 71 | 21.6% | 175 | 53.4% | ||
| Gender | 0.248 | ||||||||
| M | 190 | 50 | 26.3% | 35 | 18.4% | 105 | 55.3% | ||
| F | 138 | 32 | 23.2% | 36 | 26.1% | 70 | 50.7% | ||
| Age (years) | 0.539 | ||||||||
| <1 | 4 | 2 | 25.0% | 1 | 25.0% | 2 | 50.0% | ||
| 1–10 | 287 | 68 | 23.7% | 62 | 21.6% | 157 | 54.7% | ||
| >10 | 37 | 12 | 32.4% | 8 | 21.6% | 17 | 45.9% | ||
| Chromosome hyperdiploidy* | <0.0001 | ||||||||
| N | 174 | 54 | 31.0% | 48 | 27.6% | 72 | 41.4% | ||
| Y | 60 | 4 | 6.7% | 4 | 6.7% | 52 | 86.7% | ||
| Molecular abnormality | <0.0001 | ||||||||
| ETV6/RUNX1 fusion | 61 | 21 | 34.4% | 19 | 31.1% | 21 | 34.4% | ||
| BCR/ABL1 fusion | 14 | 4 | 28.6% | 6 | 42.9% | 4 | 28.6% | ||
| E2A/PBX1 fusion | 22 | 19 | 86.4% | 3 | 13.6% | 0 | 0.0% | ||
| KMT2A- rearrangement | 9 | 3 | 33.3% | 3 | 33.3% | 3 | 33.3% | ||
| HOX11 | 19 | 1 | 5.3% | 2 | 10.5% | 16 | 84.2% | ||
| Mixed** | 1 | 0 | 0.0% | 0 | 0.0% | 1 | 100% | ||
| WBC (×109/L) | 0.015 | ||||||||
| WBC<20 | 199 | 38 | 19.1% | 43 | 21.6% | 118 | 59.3% | ||
| 20<WBC<50 | 60 | 16 | 26.7% | 15 | 25.0% | 29 | 48.3% | ||
| 50<WBC<100 | 37 | 15 | 40.5% | 6 | 16.2% | 16 | 43.2% | ||
| WBC>100 | 30 | 13 | 43.3% | 7 | 23.3% | 10 | 33.3% | ||
| Risk group | 0.004 | ||||||||
| SR | 86 | 13 | 15.1% | 17 | 19.8% | 56 | 65.1% | ||
| IR | 128 | 35 | 27.3% | 28 | 21.9% | 65 | 50.8% | ||
| HR | 106 | 31 | 29.2% | 24 | 22.6% | 51 | 48.1% | ||
| Day 15 BM remission† | 0.068 | ||||||||
| M1 | 164 | 49 | 29.9% | 36 | 22.0% | 79 | 48.2% | ||
| M2 | 96 | 16 | 16.7% | 17 | 17.7% | 63 | 65.6% | ||
| M3 | 61 | 15 | 24.6% | 15 | 24.6% | 31 | 50.8% | ||
| Day 33 BM remission‡ | 0.599 | ||||||||
| N | 296 | 72 | 24.3% | 67 | 22.6% | 157 | 53% | ||
| Y | 15 | 5 | 33.3% | 2 | 13.3% | 8 | 53.3% | ||
| Day 33 MRD level# | 0.147 | ||||||||
| <0.01% | 172 | 43 | 25.0% | 34 | 19.8% | 95 | 55.2% | ||
| 0.01–1% | 111 | 18 | 16.2% | 25 | 22.5% | 68 | 61.3% | ||
| >1% | 14 | 6 | 42.9% | 3 | 21.4% | 5 | 35.7% | ||
| Week 12 MRD level## | 0.576 | ||||||||
| <0.1% | 246 | 54 | 22.0% | 49 | 19.9% | 143 | 58.1% | ||
| >0.1% | 31 | 8 | 25.8% | 8 | 25.8% | 15 | 48.4% | ||
| Steroid response§ | 0.634 | ||||||||
| Sensitive | 284 | 69 | 24.3% | 61 | 21.5% | 154 | 54.2% | ||
| Resistant | 41 | 12 | 29.3% | 10 | 24.4% | 19 | 46.3% | ||
| Relapse | 0.051 | ||||||||
| N | 272 | 62 | 22.8% | 57 | 21.0% | 153 | 56.3% | ||
| Y | 56 | 20 | 35.7% | 14 | 25.0% | 22 | 39.3% | ||
| Death | 0.005 | ||||||||
| N | 279 | 66 | 23.7% | 54 | 19.4% | 159 | 57.0% | ||
| Y | 49 | 16 | 32.7% | 17 | 34.7% | 16 | 32.7% | ||
*No metaphase cell available for karyotyping in 94 patients.
**One case with KMT2A/AF10 rearrangement and HOX11.
†Patients lacking D15 BM status data were excluded.
‡Patients lacking D33 BM status data were excluded.
#No specific marker suitable for MRD monitoring in seven patients.
##No specific marker suitable for MRD monitoring in seven patients and no MRD data available in 10 patients.
§Undetermined drug response in three patients.
WBC, white blood cell; SR, standard risk; IR, intermediate risk; HR, high risk; MRD, minimal residual disease.
Bold numbers represent that p value reaches statistical significance.